Kymab, Gates Foundation to team up for malaria, HIV antigen discovery

Bill Gates

Thanks to a Series B round from Wellcome Trust and the Bill & Melinda Gates Foundation, U.K. biotech Kymab has some new vaccine research plans. Each organization has pledged $20 million to support the company's Kymouse technology, a genetically engineered mouse platform that allows scientists to generate human antibodies against a range of targets. And with the new funds, Kymab will join up with the Gates Foundation to search for new vaccine antigens, focusing at first on malaria and HIV. Release | More from FierceBiotech

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.